Read the most important and the latest news about CERVANTES trial here

I. The CERVANTES team prepared protocol amendment (version v2.0) which should speed up patient enrolment, eliminate patients drop out and set mandatory adjuvant treatment. The two main changes include:

• A. Registration of patients into the study only after surgery: this approach allows for more precise selection of suitable candidates for the study as all inclusion criteria are known based on the final histological examination. This increases the overall validity of the results obtained and eliminates patients drop out.

• B. Establishment of a minimum standard for adjuvant treatment - external pelvic radiotherapy (EBRT): that is internationally recognised standard for adjuvant treatment in these patients; this adjustment ensures that all patients included in the study receive appropriate and consistent treatment in accordance with current guidelines. Moreover, this also means that Cervantes is no longer a pharmacological trial and appropriate approval of such a trial lies in hands of Institutional Review Boards (IRBs).

This protocol was approved by our local ethics committee and EMA (CTIS).

II. We got together!

The CERVANTES team was attending the ESGO 2025 conference in Rome and prepared a meeting where we introduced the protocol amendment and provided current status update.